Health TrialsbyHealthPanel

Vaccine-induced Immunity in Immunocompromised Patients

ConditionImmunodeficiency
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Cologne

About this trial

Managing respiratory virus infections in immunocompromised patients requires a multidisciplinary approach, including vaccination, though its effectiveness is often suboptimal in these individuals.

In hematological patients, poor humoral immunogenicity is common, especially when the B cell axis is affected by disease or treatment, while T cell responses may offer better protection. Current immunologic data on these patients is limited, focusing mostly on serologic parameters. To address this, we will conduct an observational study analyzing early and late booster vaccinations, with a focus on virus-specific T cell responses in vaccinated patients.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Signed informed consent form

Patients with immunosuppression either by treatment or underlying diseases

Patients who are vaccinated or willing to be vaccinated against respiratory virus infections in ac-cordance with current recommendations

Age of 18 years or older

Disqualifiers

Patients unwilling/ineligible for vaccination under current recommendations

Trial population

Immunocompromised patients vaccinated against respiratory virus infections or willing to be vaccinated

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Humoral immune response after vaccination

To compare antibody titres between different subgroups of immunocompromised patients after vaccination against respiratory virus infections

Time frame
12 months

Secondary outcomes

1

Cellular immune response after vaccination

To analyse T cell response after vaccination against respiratory virus infections

Time frame
12 months
2

Seroconversion

To compare antibody response rates between dif-ferent subgroups of immunocompromised patients after vaccination against respiratory virus infections

Time frame
12 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Cologne

Lead sponsor

Source ClinicalTrials.gov
Apply now